Compare BLX & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLX | GRDN |
|---|---|---|
| Founded | 1977 | 2004 |
| Country | Panama | United States |
| Employees | N/A | 3400 |
| Industry | Commercial Banks | Retail-Drug Stores and Proprietary Stores |
| Sector | Finance | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 1997 | N/A |
| Metric | BLX | GRDN |
|---|---|---|
| Price | $50.26 | $33.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $33.33 |
| AVG Volume (30 Days) | 115.7K | ★ 157.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.50% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.11 | $19.50 |
| Revenue Next Year | $10.13 | N/A |
| P/E Ratio | ★ $8.26 | $117.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.14 | $17.78 |
| 52 Week High | $51.99 | $37.43 |
| Indicator | BLX | GRDN |
|---|---|---|
| Relative Strength Index (RSI) | 57.79 | 56.50 |
| Support Level | $43.50 | $31.82 |
| Resistance Level | $51.99 | $34.98 |
| Average True Range (ATR) | 1.33 | 1.19 |
| MACD | -0.12 | -0.09 |
| Stochastic Oscillator | 52.73 | 50.47 |
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.